Skip to main content

Advertisement

Table 9 Thromboprophylaxes

From: Risk factors for venous thromboembolism of total hip arthroplasty and total knee arthroplasty: a systematic review of evidences in ten years

Risk factors (thromboprophylaxes) Studies reporting on a risk factor for THA or TKA: total number, number reporting a significant (p ≤ .05) increased (+) or decreased (−) risk, and number with no significant association (p > .05)
THA TKA
N p ≤ .05 p > .05 N p ≤ .05 p > .05
  + -    + -  
Chemoprophylaxis (vs. no-prophylaxis) 3 0 2 1 3 0 2 1
Enoxaparin (vs. other LMWH) 3 0 1 2 3 0 1 2
Low-dose LMWH (vs. high-dose LMWH) - - - - 1 0 0 1
Preoperative LMWH (vs. Postoperative) 1 0 0 1 2 0 0 2
Oligosaccharides* (vs. LMWH) 2 0 2 0 1 0 0 1
Direct factor-Xa inhibitor (vs. LMWH) 5 0 4 1 5 1 2 2
Direct factor-II inhibitor (vs. LMWH) 2 0 1 1 2 1 0 1
Partial factor-VII inhibitor (vs. LMWH) - - - - 1 0 1 0
NSAIDS (vs. LMWH) 2 0 0 2 1 0 0 1
VKA (vs. NSAIDS) - - - - 1 1 0 0
ACCP-recommended prophylaxis (vs. others ) 1 0 1 0 1 0 1 0
Extended prophylaxis (vs. short) 1 0 1 0 2 0 2 0
Mechanical prophylaxis (vs. chemoprophylaxis) 1 0 0 1 - - - -
Below-knee stockings (vs. up-knee) - - - - 1 0 0 1
Earlier mobilization 2 0 2 0 3 0 3 0
Weight bearing within 48 h 1 0 0 1 1 0 0 1
  1. *Oligosaccharides include fondaparinux and SR123781A (a synthetic oligosaccharide).
  2. Extended/short prophylaxis has two kinds of definations:
  3. 1. Thromboprophylaxis continued to Day 30 ± 5/Day 10 ± 2;
  4. 2. Thromboprophylaxis lasting > 14d/<14d.